Elanco Animal Health Incorporated

Elanco Animal Health Incorporated is a global leader in animal health, dedicated to innovating, developing, manufacturing, and marketing products and services for pets and farm animals. The company's mission is to enrich lives through food and companionship, striving to make life better for animals, which in turn makes life better for all. Headquartered in Indianapolis, Indiana, Elanco recently opened its new global headquarters in downtown Indianapolis in October 2025.

Elanco offers a diverse portfolio of solutions, including vaccines, parasiticides, antimicrobials, specialty therapeutics, nutritional enzymes, medicated feed additives, and digital tools. Its market segments are broadly divided into Pet Health, serving dogs and cats, and Farm Animal, focusing on cattle, poultry, swine, and sheep. Key products include the Credelio Family, Galliprant, Seresto, Zenrelia, and Experior, among many others. The company's strategic acquisition of Bayer Animal Health in 2020 significantly balanced its portfolio, resulting in a near-even split between companion and food animal products.

Under the leadership of President and CEO Jeff Simmons, Elanco is positioned as the third-largest animal health company globally. The company was recognized as the Animal Health Company of the Year for 2025 by S&P Global's Animal Health Awards and featured on Newsweek's America's Most Charitable Companies 2026 list. Elanco continues to emphasize innovation, with recent product launches like Zenrelia and Credelio Quattro driving significant revenue growth and a strategic focus on doubling revenue from its "Big 6" potential blockbuster products by 2028.